The European Commission, the Heads of Medicines Agencies and the European Medicines Agency have recently launched an initiative, Accelerating Clinical Trials in the European Union (ACT EU), to transform how clinical trials are initiated, designed and run.
Building on the application of the Clinical Trials Regulation and the launch of the Clinical Trials Information System (CTIS) on 31 January 2022, ACT EU will strengthen the European environment for clinical trials, whilst maintaining the high-level of protection of trial participants, data robustness and transparency. The ACT EU strategy paper recently published lists ten priority actions for 2022/2023, including enabling innovative trial methods, establishing a multi-stakeholder platform and supporting the modernisation of good clinical practice.
Together, they will contribute to achieving the ambitious goals for innovation in clinical trials set out in the European medicines agencies network strategy (EMANS) to 2025 and the European Commission’s Pharmaceutical Strategy.
Discover more by reading the strategy paper here!